Amyotrophic lateral sclerosis (ALS) is a progressive nervous system disorder. It gradually destroys the nerves responsible for muscle movement. Over time, ALS leads to almost total paralysis of muscle movement, including breathing.
Prognosis is poor in most cases because of the progressive nature of the condition. Eventually, the disorder leads to respiratory failure. After diagnosis, life span ranges from 2 to 5 years. The five-year survival rate ranges from 14% to 25%. Up to 10% of patients will survive more than 10 years. In general, the younger the age of onset, the slower the disease progresses.
The Nervous System
Copyright © Nucleus Medical Media, Inc.
The cause of ALS is unknown. In a small number of cases, it appears that genes may play a role. Also, research has shown that there may be a reduced response to cell stress and cell toxicity. The reduced response may be due to a build-up of certain protein in the brain.
A risk factor is something that increases your chance of getting a disease or condition. Risk factors include:
Symptoms of ALS include:
The doctor will ask about your symptoms and medical history and perform a physical exam. There are no tests that definitively diagnose ALS.
Tests may be used to rule out other medical conditions. These tests may include:
There is currently no cure for ALS.
Some treatment may help to reduce or manage symptoms for a time. For you and your family, a multidisciplinary approach may work best. This approach may include:
Treatment options include:
The drug riluzole has been approved for ALS. Clinical trials reveal a modest lengthening of survival. The drug may slightly improve functioning, but it does not stop the disease from progressing. Other drugs are also being studied.
Your doctor may prescribe these medicines for symptoms:
Supportive care may be needed as ALS progresses including:
ALS Association
http://www.alsa.org/
National Institute of Neurological Disorders and Stroke
http://www.ninds.nih.gov/
ALS Society of British Columbia
http://www.alsbc.ca/
ALS Society of Canada
http://www.als.ca/
Aggarwal, SP, Zinman L, Simpson E, et al. Clinical trial testing lithium in ALS terminates early for futility. Lancet Neurol. 2010; 9(5): 481-488.
Amyotrophic lateral sclerosis. EBSCO DynaMed website. Available at: https://dynamed.ebscohost.com/. Updated January 11, 2012. Accessed September 8, 2012.
Amyotrophic lateral sclerosis fact sheet. National Institute of Neurological Disorders and Stroke website. Available at: http://www.ninds.n.... Accessed September 8, 2012.
Bradley WG, Daroff RB. Neurology In Clinical Practice. Philadelphia, PA: Butterworth Heinemann Publishing; 2004.
Kasper DL, Braunwald E, Fauci AS, et al. Harrison's Principles of Internal Medicine. 16th ed. New York, NY: The McGraw-Hill Companies; 2005.
Miller RG, Mitchell JD, Lyon M, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). The Cochrane Library. Chichester, England: John Wiley & Sons, Ltd; 2005.
Samuels MA, Feske SK. Office Practice of Neurology. Philadelphia, PA: Churchill Livingstone; 2003.
Sathasivam S. Managing patients with amyotrophic lateral sclerosis. Eur J Intern Med. 2009;24:355-358.
Walling AD. Amyotrophic lateral sclerosis: Lou Gehrig's disease. Am Fam Physician. 1999;59:1489-1496.
4/17/2008 DynaMed Systematic Literature Surveillance https://dynamed.ebscohost.com/about/about-us: Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2008;105:2052-2057.
1/14/2011 DynaMed's Systematic Literature Surveillance https://dynamed.ebscohost.com/about/about-us: Mateen FJ, Carone M, Sorenson EJ. Patients who survive 5 years or more with ALS in Olmsted County, 1925-2004. J Neurol Neurosurg Psychiatry. 2010;81(10):1144-1146.
Last reviewed October 2012 by Rimas Lukas, MD
Last Updated: 10/11/2012